» Articles » PMID: 33956965

Colonization With Fluoroquinolone-Resistant Enterobacterales Decreases the Effectiveness of Fluoroquinolone Prophylaxis in Hematopoietic Cell Transplant Recipients

Abstract

Background: Levofloxacin prophylaxis is recommended to prevent gram-negative bloodstream infections (BSIs) in patients with prolonged chemotherapy-induced neutropenia. However, increasing fluoroquinolone resistance may decrease the effectiveness of this approach.

Methods: We assessed the prevalence of colonization with fluoroquinolone-resistant Enterobacterales (FQRE) among patients admitted for hematopoietic cell transplantation (HCT) from November 2016 to August 2019 and compared the risk of gram-negative BSI between FQRE-colonized and noncolonized patients. All patients received levofloxacin prophylaxis during neutropenia. Stool samples were collected upon admission for HCT and weekly thereafter until recovery from neutropenia, and underwent selective culture for FQRE. All isolates were identified and underwent antimicrobial susceptibility testing by broth microdilution. FQRE isolates also underwent whole-genome sequencing.

Results: Fifty-four of 234 (23%) patients were colonized with FQRE prior to HCT, including 30 of 119 (25%) allogeneic and 24 of 115 (21%) autologous HCT recipients. Recent antibacterial use was associated with FQRE colonization (P = .048). Ninety-one percent of colonizing FQRE isolates were Escherichia coli and 29% produced extended-spectrum β-lactamases. Seventeen (31%) FQRE-colonized patients developed gram-negative BSI despite levofloxacin prophylaxis, compared to only 2 of 180 (1.1%) patients who were not colonized with FQRE on admission (P < .001). Of the 17 gram-negative BSIs in FQRE-colonized patients, 15 (88%) were caused by FQRE isolates that were genetically identical to the colonizing strain.

Conclusions: Nearly one-third of HCT recipients with pretransplant FQRE colonization developed gram-negative BSI while receiving levofloxacin prophylaxis, and infections were typically caused by their colonizing strains. In contrast, levofloxacin prophylaxis was highly effective in patients not initially colonized with FQRE.

Citing Articles

The Prevalence of Multidrug Resistance in Enterobacterales Is Higher in Patients Undergoing Hematopoietic Stem Cell Transplantation.

Andermann T, Brown D, Holowka T, Bartelt L, Serody J, Armistead P Open Forum Infect Dis. 2025; 12(1):ofae760.

PMID: 39817037 PMC: 11733684. DOI: 10.1093/ofid/ofae760.


Management of febrile neutropenia: consensus of the Brazilian Association of Hematology, Blood Transfusion and Cell Therapy - ABHH.

Nucci M, Arrais-Rodrigues C, Bergamasco M, Garnica M, Gloria A, Guarana M Hematol Transfus Cell Ther. 2024; 46 Suppl 6:S346-S361.

PMID: 39694764 PMC: 11726106. DOI: 10.1016/j.htct.2024.11.119.


Pre-engraftment bacteremia after allogeneic hematopoietic cell transplantation without primary fluoroquinolone antibacterial prophylaxis.

Nguyen A, Fender J, Courjon J, Fischer A, Mappoura M, Morin S Transpl Infect Dis. 2024; 26(6):e14375.

PMID: 39312267 PMC: 11666864. DOI: 10.1111/tid.14375.


Patterns of fluoroquinolone utilization and resistance in a tertiary care hospital: a retrospective cross-sectional analysis study from a developing country.

Aiesh B, Zuhour A, Omar M, Hamad M, Abutaha A, Al-Jabi S BMC Infect Dis. 2024; 24(1):856.

PMID: 39179971 PMC: 11342551. DOI: 10.1186/s12879-024-09749-4.


The intestinal microbiota and cellular therapy: implications for impact and mechanisms.

Xie J, Smith M Blood. 2024; 144(15):1557-1569.

PMID: 39141827 PMC: 11830981. DOI: 10.1182/blood.2024024219.


References
1.
Chong Y, Shimoda S, Yakushiji H, Ito Y, Aoki T, Miyamoto T . Clinical impact of fluoroquinolone-resistant Escherichia coli in the fecal flora of hematological patients with neutropenia and levofloxacin prophylaxis. PLoS One. 2014; 9(1):e85210. PMC: 3898953. DOI: 10.1371/journal.pone.0085210. View

2.
Rangaraj G, Granwehr B, Jiang Y, Hachem R, Raad I . Perils of quinolone exposure in cancer patients: breakthrough bacteremia with multidrug-resistant organisms. Cancer. 2010; 116(4):967-73. DOI: 10.1002/cncr.24812. View

3.
Van Besien K, Bachier-Rodriguez L, Satlin M, Brown M, Gergis U, Guarneri D . Prophylactic rituximab prevents EBV PTLD in haplo-cord transplant recipients at high risk. Leuk Lymphoma. 2019; 60(7):1693-1696. DOI: 10.1080/10428194.2018.1543877. View

4.
Mehlhorn A, Brown D . Safety concerns with fluoroquinolones. Ann Pharmacother. 2007; 41(11):1859-66. DOI: 10.1345/aph.1K347. View

5.
Sanchez G, Babiker A, Master R, Luu T, Mathur A, Bordon J . Antibiotic Resistance among Urinary Isolates from Female Outpatients in the United States in 2003 and 2012. Antimicrob Agents Chemother. 2016; 60(5):2680-3. PMC: 4862481. DOI: 10.1128/AAC.02897-15. View